Insider Buying: Radius Health, Inc. (RDUS) Major Shareholder Acquires 50,000 Shares of Stock
Radius Health, Inc. (NASDAQ:RDUS) major shareholder Growth N. V. Biotech acquired 50,000 shares of the company’s stock in a transaction dated Tuesday, September 5th. The shares were bought at an average cost of $36.75 per share, for a total transaction of $1,837,500.00. Following the completion of the acquisition, the insider now directly owns 5,298,799 shares of the company’s stock, valued at $194,730,863.25. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.
Radius Health, Inc. (RDUS) traded down 2.21% on Thursday, reaching $36.25. 577,791 shares of the company were exchanged. Radius Health, Inc. has a 52 week low of $31.58 and a 52 week high of $59.22. The stock has a 50-day moving average price of $38.85 and a 200 day moving average price of $39.47. The stock’s market capitalization is $1.58 billion.
Radius Health (NASDAQ:RDUS) last announced its earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($1.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.35) by $0.23. The business had revenue of $0.98 million for the quarter, compared to the consensus estimate of $1.96 million. During the same period in the prior year, the firm posted ($1.01) EPS. Analysts forecast that Radius Health, Inc. will post ($5.51) earnings per share for the current year.
A number of equities research analysts have recently weighed in on RDUS shares. Cantor Fitzgerald set a $65.00 price objective on shares of Radius Health and gave the company a “buy” rating in a report on Monday, May 22nd. Maxim Group set a $24.00 price objective on shares of Radius Health and gave the company a “sell” rating in a report on Wednesday, May 24th. Zacks Investment Research lowered shares of Radius Health from a “hold” rating to a “sell” rating in a report on Tuesday, July 4th. Canaccord Genuity reissued a “buy” rating and set a $85.00 price objective on shares of Radius Health in a report on Monday, May 22nd. Finally, BidaskClub raised shares of Radius Health from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $53.60.
Institutional investors and hedge funds have recently made changes to their positions in the business. Ameritas Investment Partners Inc. acquired a new position in Radius Health during the first quarter worth about $105,000. Sei Investments Co. raised its position in Radius Health by 27.7% during the second quarter. Sei Investments Co. now owns 3,180 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 690 shares during the last quarter. Advisor Group Inc. raised its position in Radius Health by 267.2% during the second quarter. Advisor Group Inc. now owns 3,969 shares of the biopharmaceutical company’s stock worth $180,000 after acquiring an additional 2,888 shares during the last quarter. Envestnet Asset Management Inc. raised its position in Radius Health by 1.1% during the first quarter. Envestnet Asset Management Inc. now owns 4,231 shares of the biopharmaceutical company’s stock worth $163,000 after acquiring an additional 46 shares during the last quarter. Finally, Blair William & Co. IL acquired a new position in Radius Health during the second quarter worth about $205,000.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health Inc. and related companies with MarketBeat.com's FREE daily email newsletter.